Trial reportBritish journal of cancer2005
Galectin-3 immunodetection in follicular thyroid neoplasms: a prospective study on fine-needle aspiration samples.
Trial report in British journal of cancer, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Systematic Review and Meta-Analysis to Identify the Immunocytochemical Markers Effective in Delineating Benign from Malignant Thyroid Lesions in FNAC Samples.Endocrine pathology · 2022Pooled it
- Expression of CK-19, galectin-3 and HBME-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis.Diagnostic pathology · 2012Pooled it
- Cytological biomarkers and risk of malignancy in indeterminate thyroid nodules: a systematic review and meta-analysis.Endocrine oncology (Bristol, England) · 2026Review
- Core Needle Biopsy (CNB) and Immunohistochemical Markers in Indeterminate Thyroid Nodules: Evidence and Perspectives.Endocrine, metabolic & immune disorders drug targets · 2026Review
- A Pilot Study of Galectin-3, HBME-1, and p27 Triple Immunostaining Pattern for Diagnosis of Indeterminate Thyroid Nodules in Cytology With Correlation to Histology.Applied immunohistochemistry & molecular morphology : AIMM · 2015Article
- Serum Galectin-3: diagnostic value for papillary thyroid carcinoma.Ulusal cerrahi dergisi · 2015Article
- Diagnostic and prognostic markers in differentiated thyroid cancer.Current genomics · 2011Article
- Diagnostic utility of galectin-3 in thyroid cancer.The American journal of pathology · 2010Review
- Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules.Diagnostic pathology · 2010Article
- Differential expression of galectin-3, CK19, HBME1, and Ret oncoprotein in the diagnosis of thyroid neoplasms by fine needle aspiration biopsy.CytoJournal · 2009Article
- What is New on Thyroid Cancer Biomarkers.Biomarker insights · 2008Article
- Microarray analysis of thyroid nodule fine-needle aspirates accurately classifies benign and malignant lesions.The Journal of molecular diagnostics : JMD · 2006Article
- Large needle aspiration biopsy and galectin-3 determination in selected thyroid nodules with indeterminate FNA-cytology.British journal of cancer · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fine-needle aspiration cytology, which is well established to be accurate for the diagnosis of thyroid cancer, may be inconclusive for the follicular thyroid neoplasms. As galectin-3 was suggested to be a marker of malignant thyrocytes, we investigated whether this protein might be helpful in the diagnosis of aspirates classified as undeterminate by cytology. After establishing an easy processing of aspirates for galectin-3 immunodetection, a series of aspirates categorised as benign (n=63), malignant (n=17) or undeterminate (n=34) was prospectively analysed for galectin-3. Only the patients with malignant or undeterminate lesions underwent surgery. Most lesions (86%) diagnosed as malignant by cytology or after surgery were positive for galectin-3. The majority of lesions (94%) classified as benign by cytology or after surgery was negative for galectin-3. The positive and negative predictive values were 83 and 95%, respectively. When focusing on the undeterminate lesions, the sensitivity and specificity were 75 and 90%, respectively, while the positive and negative predictive values were 82 and 87%, respectively. The specificity and the positive predictive value were higher (100%) when considering the percentage of stained cells. Altogether these results show that galectin-3 constitutes a useful marker in the diagnosis of thyroid lesions classified as undeterminate by conventional cytology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.